Benzinga's Top #PreMarket Losers

Retrophin

shares declined 6.82% to $11.00 in pre-market trading following the announcement of temporary halt of RE-024 patient dosing. Isis Pharmaceuticals

dipped 3.82% to $34.99 in pre-market trading after gaining 0.78% on Thursday. The decline in the stock may be attributed to Seeking Alpha article. E. I. du Pont de Nemours and Company

fell 2.95% to $65.70 in pre-market trading after the company cut its profit guidance for the second-quarter and year. AmSurg

dropped 1.11% to $45.29 in pre-market trading after the company priced 8.5 million share offering at $45.00 per share. Baird upgraded Amsurg from Neutral to Outperform and raised the price target from $44.00 to $55.00.